Most Read Articles
Roshini Claire Anthony, 11 Sep 2019

Beta-blockers could reduce mortality risk in patients with heart failure with reduced ejection fraction (HFrEF) and moderate or moderately-severe renal dysfunction without causing harm, according to the BB-META-HF* trial presented at ESC 2019.

Elvira Manzano, 15 hours ago

The US Preventive Services Task Force (USPSTF), in an update of its 2013 recommendations, called on clinicians to offer risk-reducing medications to women who are at increased risk for breast cancer but at low risk for adverse effects.

Pearl Toh, Yesterday
The use of SGLT-2* inhibitors was not associated with a higher risk of severe or nonsevere urinary tract infections (UTIs) in patients with type 2 diabetes (T2D) compared with DPP**-4 inhibitors or GLP-1*** receptor agonists, a population-based cohort study shows.
Stephen Padilla, 6 days ago
Overweight and obesity show an inverse relationship with acne in a dose-dependent manner in young adults, according to a recent study. This suggests that the metabolically active adipose tissue plays a protective role in acne.

Metformin safe for psoriatic patients with diabetes

14 Jul 2019

Clinicians need not worry about prescribing metformin for psoriatic patients with type 2 diabetes mellitus (T2DM), as results of a recent study show no safety concerns.

To examine the real-world safety of metformin in psoriatic patients with T2DM, the investigators conducted a cohort study using the National Health Insurance Research Database. All patients were divided into the metformin and the nonmetformin group based on their antidiabetic prescriptions.

The outcomes included all-cause mortality, severe psoriasis, hospitalization due to psoriasis and any cause for readmission.

A total of 5,520 and 3,062 patients were enrolled in the metformin and nonmetformin groups, respectively. No significant between-group difference was observed in terms of the risk of all-cause mortality (hazard ratio [HR], 1.08, 95 percent CI, 0.90–1.30), severe psoriasis (HR, 0.95, 0.80–1.09), psoriasis-related admission (HR, 1.32, 0.90–1.93) and any-cause readmission (HR, 0.99, 0.90–1.11).

In the dose-response analysis, there was no significant increase in the risk of severe psoriasis and psoriasis-related admission, even with prescribing >80 defined daily doses or >1,000 mg daily dose of metformin (p-trend>0.05).

A previous study involving psoriatic patients with metabolic syndrome (MS) showed that metformin is effective in improving psoriasis and parameters of MS and can be used for the benefit of this patient population. [Indian J Endocrinol Metab 2017;21:581-587]

In a cross-sectional study performed on 48 Vietnamese patients with psoriasis, results indicated that combined therapy with metformin and methotrexate significantly improved the quality of life for patients with psoriasis. [Open Access Maced J Med Sci 2019;7:302-303]

Editor's Recommendations
Most Read Articles
Roshini Claire Anthony, 11 Sep 2019

Beta-blockers could reduce mortality risk in patients with heart failure with reduced ejection fraction (HFrEF) and moderate or moderately-severe renal dysfunction without causing harm, according to the BB-META-HF* trial presented at ESC 2019.

Elvira Manzano, 15 hours ago

The US Preventive Services Task Force (USPSTF), in an update of its 2013 recommendations, called on clinicians to offer risk-reducing medications to women who are at increased risk for breast cancer but at low risk for adverse effects.

Pearl Toh, Yesterday
The use of SGLT-2* inhibitors was not associated with a higher risk of severe or nonsevere urinary tract infections (UTIs) in patients with type 2 diabetes (T2D) compared with DPP**-4 inhibitors or GLP-1*** receptor agonists, a population-based cohort study shows.
Stephen Padilla, 6 days ago
Overweight and obesity show an inverse relationship with acne in a dose-dependent manner in young adults, according to a recent study. This suggests that the metabolically active adipose tissue plays a protective role in acne.